Highly Specific and Sensitive Target Binding by the Humanized pS396-Tau Antibody hC10.2 Across a Wide Spectrum of Alzheimer’s Disease and Primary Tauopathy Postmortem Brains

Article type: Research Article

Authors: Helboe, Lone^a | Rosenqvist, Nina^a | Volbracht, Christiane^a | Pedersen, Lars Ø.^a | Pedersen, Jan T.^a | Christensen, Søren^a | Egebjerg, Jan^a | Christoffersen, Claus T.^a | Bang-Andersen, Benny^a | Beach, Thomas G.^b | Serrano, Geidy E.^b | Falsig, Jeppe^{a; *}

Affiliations: [a] H. Lundbeck A/S, Valby, Denmark | [b] Banner Sun Health Research Institute, Sun City, AZ, USA

Correspondence: [*] Correspondence to: Jeppe Falsig, H. Lundbeck A/S, Denmark. Tel.: +45 30832842; Fax: +45 36438258; E-mail: JFP@lundbeck.com.

Abstract: Background:Deposits of hyperphosphorylated tau fibrils are hallmarks of a broad spectrum of tauopathies, including Alzheimer’s disease (AD). Objective:To investigate heterogeneity of tau pathology across brain extracts from a broad selection of different tauopathies and examine the binding properties of the humanized pS396-tau antibody hC10.2 and six other anti-tau antibodies. Methods:76 individual tauopathy tissue samples were analyzed in a battery of assays: immunohistochemistry, ELISA, tau aggregation assay, western blot, [3H]PI-2620 and [3H]MK-6240 tau tracer binding, and aggregated seeding activity in RD_P301S HEK293T Biosensor cells. The efficiency of seven anti-tau antibodies to engage with pathological tau species was directly compared. Results:Our data indicate that a strong correlation existed between the tau tracer binding, amount of tau aggregates, pS396-tau phosphorylation, and seeding activity. The hC10.2 antibody, which has entered clinical development, effectively engaged with its epitope across all individual cases of mid-stage and late AD, and primary tauopathies. hC10.2 was superior compared to other phospho- and total tau antibodies to prevent seeded tau aggregation in the biosensor cells. hC10.2 effectively depleted hyperphosphorylated and aggregated tau species across all tauopathy samples proportionally to the amount of tau aggregates. In AD samples, hC10.2 bound to ghost tangles which represent extracellular pathological tau species. Conclusion:S396 hyperphosphorylation is a feature of the formation of seeding-competent tau across different tauopathies and it is present both in intra- and extracellular pathological tau. hC10.2 represents an excellent candidate for a hyperphosphorylation-selective therapeutic tau antibody for the treatment of AD and primary tauopathies.

Keywords: Alzheimer’s disease, human brain tissue, humanized antibody, PET tracer, seeding and spreading, tau aggregate, tauopathy, therapeutic monoclonal antibody

DOI: 10.3233/JAD-220125

Journal: Journal of Alzheimer's Disease, vol. 88, no. 1, pp. 207-228, 2022